Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.

Hoshi, Taisuke

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. [electronic resource] - Biochemical and biophysical research communications 05 2019 - 1-7 p. digital

Publication Type: Journal Article

1090-2104

10.1016/j.bbrc.2019.02.015 doi


Animals
Antineoplastic Agents--therapeutic use
Carcinoma, Hepatocellular--drug therapy
Cell Line, Tumor
Female
Fibroblast Growth Factors--metabolism
Humans
Liver Neoplasms--drug therapy
MAP Kinase Signaling System--drug effects
Mice
Mice, Inbred BALB C
Mice, Nude
Phenylurea Compounds--therapeutic use
Quinolines--therapeutic use
Receptors, Fibroblast Growth Factor--metabolism
Signal Transduction--drug effects